← FDA DRUG APPROVALS
FDA ANDA · ANDA214058
EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
Sponsor: CIPLA LIMITED
APPLICATION
ANDA214058
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDENone (Tentative Approval)
EMTRICITABINE 200MG, RILPIVIRINE 25MG, TENOFOVIR ALAFENAMIDE 25MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.